Scarica l'app Stockscreener
198.64
0.00%
0.00
Dopo l'orario di chiusura:
198.97
0.33
+0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$198.64
Aprire:
$198.09
Volume 24 ore:
3.05M
Relative Volume:
0.50
Capitalizzazione di mercato:
$350.91B
Reddito:
$58.33B
Utile/perdita netta:
$3.76B
Rapporto P/E:
94.59
EPS:
2.1
Flusso di cassa netto:
$18.24B
1 W Prestazione:
+0.05%
1M Prestazione:
+3.22%
6M Prestazione:
+2.92%
1 anno Prestazione:
+4.45%
Intervallo 1D:
$197.05
$200.02
Intervallo di 1 settimana:
$194.67
$200.33
Portata 52W:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
198.64 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
639.43 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
NVS
Novartis Ag Adr
|
119.31 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.30 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie To Invest $195 Mln In Illinois API Manufacturing Expansion - Nasdaq
C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Novartis, Apollomics Inc., Abbvie, Janssen Research and Developm - Barchart.com
AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition (NYSE:ABBV) - Seeking Alpha
AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients - Yahoo Finance
AbbVie details nearly $200M API plant as part of new US investments - Endpoints News
AbbVie to invest $195M in North Chicago manufacturing expansion - The Business Journals
Illinois secures AbbVie’s $195 million investment for North Chicago facility - MyStateline
AbbVie to invest $195M to build plant in Illinois - MSN
AbbVie to invest $195M to build plant in Illinois (ABBV:NYSE) - Seeking Alpha
AbbVie investing $195 million to expand manufacturing footprint in Illinois - Daily Herald
AbbVie to invest $195 million in expanding Illinois facility - WICS
AbbVie plans $195M expansion of North Chicago plant in U.S. production push - Crain's Chicago Business
AbbVie plans $195M API plant in Illinois as part of US investment campaign - Fierce Pharma
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. - Investing News Network
AbbVie announces $195 mln investment to expand active pharmaceutical ingredient manufacturing in U.S. - MarketScreener
AbbVie Invests $195 Million to Construct New Manufacturing Facility in Illinois - MarketScreener
AbbVie's Strategic API Expansion and U.S. Supply Chain Resilience: A New Era for Pharmaceutical Sector Valuation - AInvest
AbbVie to invest $195 million in North Chicago manufacturing expansion By Investing.com - Investing.com Canada
AbbVie invests $195 million in US manufacturing facility expansion - StreetInsider
Short Bowel Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire, AbbVie, Hanmi Pharma - Barchart.com
Piper Sandler starts AbbVie as it sees growth shielded from drug patent losses - Investing.com Canada
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Autoinjectors Market Set to Surpass USD 3.02 Billion by 2030 as Demand for Advanced Drug Delivery Systems Accelerates | MarketsandMarkets™. - GlobeNewswire Inc.
AbbVie Gains New Bullish Coverage As Stock Looks To Test $200 - AskTraders.com
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - GlobeNewswire
AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments - TipRanks
Piper Sandler assumes coverage of Abbvie stock with Overweight rating By Investing.com - Investing.com Canada
AbbVie Surges 0.3% on Earnings and Acquisition Hopes as $1.2B Volume Hits Top 500 Rank - AInvest
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape - Barchart.com
AbbVie’s upadacitinib raises the bar for alopecia areata - Yahoo Finance
4 Overlooked Dividend Aristocrat Stocks with Up To 60%+ Growth Potential - 24/7 Wall St.
AbbVie’s Drug Upadacitinib Shows Positive Phase 3 Results for Severe Alopecia Areata Treatment - Insider Monkey
AbbVie Secures FDA Approval to Expand Mavyret’s Label - MSN
This Insider Has Just Sold Shares In AbbVie - simplywall.st
AbbVie’s Upcoming Study on ABBV-932: What Investors Need to Know - TipRanks
Stock Analysis | Abbvie OutlookA Strong Fundamentals Picture Amid Mixed Analyst Sentiment - AInvest
AbbVie's $0.81B Volume Ranks 104th as Stock Falls 0.41% on Mixed Earnings and Analyst Upgrades - AInvest
AbbVie-Genmab cancer collab shows promising results - Crain's Chicago Business
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win - insights.citeline.com
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules - Benzinga
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
AbbVie and Genmab’s Promising B-Cell Lymphoma Trial: A Potential Game-Changer? - The Globe and Mail
AbbVie and Genmab’s Promising Phase 3 Trial for Follicular Lymphoma - The Globe and Mail
AbbVie’s Immunotherapy Trial: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
AbbVie’s Duodopa Study: A Deep Dive into Parkinson’s Treatment - TipRanks
AbbVie Advances Glaucoma Treatment with XEN63 Gel Stent Study - TipRanks
AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa - TipRanks
AbbVie’s Skyrizi rises to the top for pharma TV ad impressions - Medical Marketing and Media
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):